Science News & Science Current Events
 
Email a Friend Send to a friend
Printer Friendly Print What change does prokineticin 2/Bv8 have in human hepatocellular carcinoma?

What change does prokineticin 2/Bv8 have in human hepatocellular carcinoma?

March 18, 2008

Liver hepatocarcinoma is a highly vascularized cancer, and more and more research is focused on the molecules controlling angiogenesis. In 2001, two novel peptides, known as prokineticin 1/EG-VEGF (PK1/EG-VEGF) and prokineticin 2/Bv8 (PK2/Bv8), were identified, as having potent angiogenic activities. The angiogenic potential of these two peptides during human hepatocellular carcinoma progression was evaluated. These findings show, that only, PK2/Bv8 is expressed in liver and -- surprisingly -- that its expression decreases during hepatocellular carcinoma. Furthermore, these results show that PK2/Bv8 expression is restricted specifically to liver resident macrophages, thus suggesting a role in Kuppfer cell physiology.

This study, performed by a team lead by Dr. Michel Samson and his colleagues at the INSERM U620 unit located at the University of Rennes, to be published on February 28, 2008 in the World Journal of Gastroenterology.




Angiogenesis has become a promising anti-cancer strategy, because in adults novel blood vessels are only formed as the tumor is growing, and not in the surrounding healthy tissue. Identifying novel molecules involved in tumoral angiogenesis will, therefore, allow for new therapeutic targets. PK1/EG-VEGF and PK2/Bv8 are novel peptides with potent angiogenic effects. They have been shown to be upregulated in several types of cancer such as neuroblastoma, prostate, and leydig cell tumors. However, there angiogenic potential has not yet been studied in the context of hepatocellular carcinoma.

According to the authors of the study, the data shown in this work are consistent with the fact that the biology of these two novel peptides is both complex and diverse. Indeed, results were surprising since, instead of observing an upregulation in hepatocellular carcinoma, the team observed a significant downregulation, and the cellular expression was not located to endothelial cells but to resident macrophages. It seems that in liver PK2/Bv8 behaves more like a cytokine than an angiogenic factor, a biological activity that has already been observed in other reports.

Recently, the first anti-angiogenic therapy, which targets secreted VEGF, has been approved by the FDA and is now used as a first line of defense in association with chemotherapy in certain types of cancer. Identifying new molecules involved in tumoral angiogenesis might in turn provide new targets for anti-angiogenic therapeutics. Furthermore, not all the molecular mechanisms underlying hepatocellular carcinoma angiogenesis are entirely understood yet. Our data show that the two novel angiogenic peptides PK1/EG-VEGF and PK2/Bv8 are not involved in hepatocellular carcinoma angiogenesis.

In this study, in order to evaluate the angiogenic potential of PK1/EG-VEGF and PK2/Bv8, gene expression was measured by real-time PCR on a human cohort counting 28 hepatocellular carcinoma patients (provided by the Centre de Ressources Biologiques de Rennes). Furthermore, PK2/Bv8 protein expression was detected in both normal liver tissue, and in isolated liver cells using antibodies anti-PK2/Bv8 provided by Dr. Feige from the INSERM U878 unit in Grenoble, France. This research was performed by doctors from the INSERM U620 Laboratory of toxicology and tissue repair of the Faculty of Pharmacy at the University of Rennes 1, France. This research was funded by INSERM, the Ministre de l¡-Education Nationale de la Recherche et de la Technologie, and the Region Bretagne.

Further research should explain more precisely how PK2/Bv8 is involved in Kupffer cell physiology.

World Journal of Gastroenterology



Related Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News Articles Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News RSS Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News RSS
How to select anti-hepatitis B virus agents for drug-resistance patients?
HBV infection may lead to acute liver disease, chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma. Over 350 million people worldwide are estimated to be infected chronically by HBV and are therefore at risk of liver failure, cirrhosis, or hepatocellular carcinoma.

A new therapeutic option for human hepatocyte cancer
p53-impaired tumors may be particularly suitable to parvovirus H-1-induced therapy. Although the p53 deficiency in tumors may induce resistance to chemotherapeutic agents, this will not affect the tumor cell susceptibility to H-1 PV-induced oncolytic infections.

To protect against liver disease, body puts cells 'under arrest'
A stable form of cell-cycle arrest known to offer potent protection against cancer also limits liver fibrosis, a condition characterized by an excess of fibrous tissue, according to a new report in the August 22nd Cell, a Cell Press publication.

Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage
Although post-reproductive life in humans is often associated with decline and a loss of powers, an analogous state in certain cells -- called senescence -- is proving to be one of ironic potency. Scientists at Cold Spring Harbor Laboratory (CSHL) today reported that a particular class of senescent liver cells orchestrates a sequence of events in living mice that can limit fibrosis, a natural response of the liver to acute damage.

New study shows potential to treat or prevent viral cancers
A new study, presented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.

CSHL scientists trace causal link between a tumor suppressor gene and liver cancer
Scientists at Cold Spring Harbor Laboratory (CSHL) have taken the search for cancer-causing genes an important step forward. In a newly published paper, they confirm that a gene called DLC1 is a tumor suppressor. They have demonstrated in living mice that its deletion, inactivation or loss precipitates events culminating in an aggressive type of liver cancer closely related to common human epithelial cancers of the liver (also known as hepatocellular carcinoma, or HCC).

Synergistic growth inhibitory effect of herbal extracts against HCC and lung cancer cells
Several herbs with diversified pharmacological properties are known to be rich sources of chemical constituents that may have potential for the treatment of several human cancers. Data from the Department of Preclinical Science, Faculty of Medicine, Thammasat University, demonstrates that the growth inhibitory activity of doxorubicin or cisplatin, as single agents, may be modified in combination with emblic myrobalan or belleric myrobalan extracts and may be synergistically enhanced in some cases.

Anti-HBe may play a role in the progression of the disease of hepatitis B
Genotype D is found to be the only detected type in different clinical forms of HBV infections, including cirrhosis, among residents of southwestern Iran. A significant association between the presence of anti-HBe antibody and increasing ALT levels among either HBeAg-negative or HBeAg-positive individuals was also determined.

High circulating D-dimers are associated with presence of ascites
The liver is the production site of most of the proteins which favour and inhibit the process of coagulation and fibrinolysis.

Study shows positive findings in treating patients with advanced hepatitis C
The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).
More Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News Articles


Hepatocellular Carcinoma

This essential book is a compendium of papers written by an international team of world-renowned experts, who cover topics in their respective areas of expertise. Presenting the most up-to-date knowledge of hepatocellular carcinoma, it covers all topics -- including those more controversial ones -- in this rapidly advancing field, from epidemiology to prevention, from molecular biology to gross...

Spontaneous regression of hepatocellular carcinoma: potential promise for the future.: An article from: Southern Medical Journal
by Harsha Gadadhar Vardhana, Mukta Panda

This digital document is an article from Southern Medical Journal, published by Thomson Gale on February 1, 2007. The length of the article is 541 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...



p53 Mutations in hepatocellular carcinoma patients in Egypt [An article from: International Journal of Hygiene and Environmental Health]
by S.A. El-Kafrawy, M. Abdel-Hamid, M. El-Daly, Nada

This digital document is a journal article from International Journal of Hygiene and Environmental Health, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: The p53 gene plays a major role in hepatocellular carcinoma (HCC). Acquired mutations may provide...



Hepatitus C Virus and Its Involvement in the Development of Hepatocellular Carcinoma: 25th International Symposium (Proceedings of the Princess Takamatsu Cancer Research Fund)



Hepatocellular Carcinoma Medical Guide
by Qontro Medical Guides

The Hepatocellular Carcinoma Medical Guide is a publication which has been designed to better help readers understand Hepatocellular Carcinoma. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Hepatocellular Carcinoma. The Hepatocellular Carcinoma Medical Guide is highly recommended for...



Hepatocellular Carcinoma/Liver Tumors, An Issue of Clinics in Liver Disease (The Clinics: Internal Medicine)
by Morris Sherman

The full spectrum of hepatocellular carcinoma is discusssed from epidemiology to prevention to indications for liver transplantation. Prevention, screening, biopsy staging, and diagnosis are all...

Hepatocellular carcinoma in a patient with human immunodeficiency virus and hepatitis B virus coinfection: an emerging problem?(Case Report): An article from: Southern Medical Journal
by Chris B. Hyun, Walter J. Coyle

This digital document is an article from Southern Medical Journal, published by Southern Medical Association on April 1, 2004. The length of the article is 3697 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Peripheral hypereosinophilia in a patient with hepatocellular carcinoma. (Letters to the Editor).(Letter to the Editor): An article from: Southern Medical Journal

This digital document is an article from Southern Medical Journal, published by Southern Medical Association on March 1, 2003. The length of the article is 1004 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...



Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma [An article from: Comparative Biochemistry and Physiology, Part C]
by Yu Kuang, S.J. Schomisch, V. Chandramouli, Z. Lee

This digital document is a journal article from Comparative Biochemistry and Physiology, Part C, published by Elsevier in 2006. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: 2-Deoxy-2-[^1^8F]fluoro-d-glucose ([^1^8F] FDG) is used for PET imaging of woodchuck (Marmota monax)...



Hepatocellular Carcinoma: Methods and Protocols (Methods in Molecular Medicine)

Nagy Habib and a team of clinical laboratorians and physicians describe the wide variety of powerful new laboratory methods currently being used for investigating and treating hepatocellular carcinoma. The book focuses on gene therapy approaches, including the use of such vectors as lipids, such viruses as adenovirus and baculovirus, and virus detection assessment using electron microscopy. It...

© 2008 BrightSurf.com